Publications by authors named "Timo Muhonen"

Claim this Profile
D
Disease-phase-specific resource utilization and healthcare costs in metastatic colorectal cancer: a subgroup analysis of the Finnish RAXO study.
Joel Kontiainen, Kaisa Lehtomäki, Timo Muhonen, Eetu Heervä, Annika Ålgars

Scand J Gastroenterol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KRAS and NRAS mutations in Nordic population-based and real-world metastatic colorectal cancer cohorts.
Emerik Osterlund, Ari Ristimäki, Luís Nunes, Soili Kytölä, Sonja Aho, Timo Muhonen

BJC Rep· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Primary Tumor Location on Demographics, Resectability, Outcomes, and Quality of Life in Finnish Metastatic Colorectal Cancer Patients (Subgroup Analysis of the RAXO Study).
Sonja Aho, Emerik Osterlund, Ari Ristimäki, Lasse Nieminen, Jari Sundström, Timo Muhonen

Cancers (Basel)· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resectability and resection rates of colorectal liver metastases according to RAS and BRAF mutational status: prospective study.
Aki Uutela, Arno Nordin, Emerik Osterlund, Päivi Halonen, Raija Kallio, Timo Muhonen

Br J Surg· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resectability, Resections, Survival Outcomes, and Quality of Life in Older Adult Patients with Metastatic Colorectal Cancer (the RAXO-Study).
Kaisa Lehtomäki, Leena-Maija Soveri, Emerik Osterlund, Annamarja Lamminmäki, Aki Uutela, Timo Muhonen

J Clin Med· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective Longitudinal Health-related Quality of Life Analysis of the Finnish Arm of the PRIAS Active Surveillance Cohort: 11 Years of Follow-up.
Utku Lokman, Hanna Vasarainen, Kanerva Lahdensuo, Andrew Erickson, Timo Muhonen

Eur Urol Focus· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resectability, conversion, metastasectomy and outcome according to RAS and BRAF status for metastatic colorectal cancer in the prospective RAXO study.
Aki Uutela, Emerik Osterlund, Päivi Halonen, Raija Kallio, Annika Ålgars, Timo Muhonen

Br J Cancer· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-Related Quality of Life in Metastatic Colorectal Cancer Patients Treated with Curative Resection and/or Local Ablative Therapy or Systemic Therapy in the Finnish RAXO-Study.
Kaisa Lehtomäki, Hanna P Stedt, Emerik Osterlund, Timo Muhonen, Leena-Maija Soveri

Cancers (Basel)· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
-
-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer.
Emerik Osterlund, Ari Ristimäki, Soili Kytölä, Teijo Kuopio, Eetu Heervä, Timo Muhonen

Front Oncol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pelvic sentinel lymph nodes have minimal impact on survival in melanoma patients.
Mikko Vuoristo, Timo Muhonen, Virve Koljonen, Susanna Juteau, Micaela Hernberg

BJS Open· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term prognostic value of sentinel lymph node tumor burden in survival of melanoma patients.
Mikko Vuoristo, Timo Muhonen, Virve Koljonen, Susanna Juteau, Micaela Hernberg

Acta Oncol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Repeated centralized multidisciplinary team assessment of resectability, clinical behavior, and outcomes in 1086 Finnish metastatic colorectal cancer patients (RAXO): A nationwide prospective intervention study.
Pia Osterlund, Tapio Salminen, Leena-Maija Soveri, Raija Kallio, Ilmo Kellokumpu, Timo Muhonen

Lancet Reg Health Eur· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life among prostate cancer patients: real-life situation at the beginning of treatment.
Susanne Bergius, Saku Torvinen, Timo Muhonen, Risto P Roine, Harri Sintonen

Scand J Urol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Letter to the editor.
Timo Muhonen

J Med Econ· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Not Available].
Timo Muhonen

Duodecim· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma.
Seppo Pyrhönen, Marjo Hahka-Kemppinen, Timo Muhonen, Väinämö Nikkanen, Sebastian Eskelin

Cancer· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunohistochemically detectable bcl-2 expression in metastatic melanoma: association with survival and treatment response.
Tatyana Vlaykova, Lauri Talve, Marjo Hahka-Kemppinen, Micaela Hernberg, Timo Muhonen

Oncology· July 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis